Determination of Regulatory Review Period for Purposes of Patent Extension; COLUMVI

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for patent extension for the human biological product COLUMVI, as required by law, following submissions to the US Patent and Trademark Office (USPTO).